Clinical trials: Metabolism and Excretion
Obesity
The Effect of Calcium on Fecal Fat and Energy Excretion
The overall purpose of this study is to examine the effect of calcium on fecal fat and energy excretion.
- Trial name
- NCT00519909
- Testing
- Dairy calcium
- Where
- Denmark
- Volunteers
- 15 people, healthy volunteers welcome
- Sponsor
- University of Copenhagen
Healthy
A Study of LY4064809 [14C]-STX-478 in Healthy Male Participants
The main purpose of this study is to conduct blood tests to measure how much STX-478 is in the bloodstream and how the body handles and eliminates it in healthy participants.
- Trial name
- NCT06901336
- Testing
- [14C]-STX-478
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Scorpion Therapeutics, a wholly owned subsidiary of Eli Lilly and Company
Bioequivalence Trial
Drug Metabolism, Excretion, and Human Body Composition of Aximus Capsules
This project will be based on the bioequivalence test of Aximus capsules, measuring the body composition indicators of healthy subjects before and after medication, and collecting urine samples from subjects at different time…
- Trial name
- NCT06307132
- Testing
- Aximus capsules（test）, Aximus capsules（reference）
- Where
- China
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Second Affiliated Hospital of Wenzhou Medical University
Non-alcoholic Fatty Liver Disease, Morbid Obesity
Ursodeoxycholic Acid in Bariatric Surgery
In an open-label trial, 20 otherwise healthy morbidly obese patients scheduled for bariatric surgery will be administered 20 mg/kg/day ursodeoxycholic acid for three weeks until the day before surgery.
- Trial name
- NCT01548079
- Testing
- Ursodeoxycholic Acid (UDCA)
- Volunteers
- 40 people
- Sponsor
- Sahlgrenska University Hospital
Cancer
Absorption, Metabolism, Excretion, and the Determination of Absolute Bioavailability of Niraparib in Subjects With Cancer
This is an open-label study with 2 parts, plus an extension study following completion of Parts 1 or 2, that is being conducted in approximately 12 subjects (6 subjects in Part 1; 6 subjects in Part 2) with cancer to examine the…
- Trial name
- NCT02476552
- Testing
- Niraparib Oral Capsules (Labeled), Niraparib IV (Labeled), Niraparib Oral Capsules (Unlabeled)
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- Tesaro, Inc.
Healthy
Mass Balance Recovery, Absorption, Metabolism and Excretion of [14C]-BLU-5937
This is a single-centre, open-label, non-randomised, single-period, single-dose study in healthy male subjects designed to assess the mass balance recovery, PK, metabolite profile and metabolite identification of [14C]-BLU-5937.
- Trial name
- NCT05244759
- Testing
- [14C]-BLU-5937
- Where
- United Kingdom
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Bellus Health Inc. - a GSK company
Pharmacokinetics of Flavonoids in Humans
An Acute Human Intervention With Flavonoid to Investigate Absorption, Metabolism and Excretion
The era of general dietary recommendations for the whole population may be coming to an end, as it is becoming apparent that we are all unique and do not respond in the same way to the same foods.
- Trial name
- COB (NCT01922869)
- Testing
- Flavonoids
- Where
- United Kingdom
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- University of East Anglia
Healthy Volunteers
A Study to Evaluate the Absorption, Metabolism, and Excretion (ADME) of BMS-986435
The purpose of this study is to determine the absorption, metabolism, excretion; and to evaluate the safety and tolerability of BMS-986435 in healthy male participants Participants will be admitted to the study site for 3 weeks.
- Trial name
- NCT05686096
- Testing
- MYK-224
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Healthy
Study to Evaluate Absorption, Metabolism and Excretion of Single-dose [14C]-Saroglitazar in Healthy Male Subjects
This will be a Phase I, open-label, nonrandomized, single-dose study in healthy male subjects.
- Trial name
- NCT04112446
- Testing
- Saroglitazar magnesium
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Zydus Therapeutics Inc.
Dementias With Lewy Bodies
A Study to Determine the Metabolism and Elimination of [14C]E2027 in Healthy Male Participants
The primary objective of the study is to achieve mass balance recovery of [14C]-radiolabel in urine and feces and to identify and quantify the main elimination pathways of E2027.
- Trial name
- NCT04023877
- Testing
- E2027
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Eisai Inc.
Diabetes Mellitus, Type 2, Obesity
Investigation Of Weight Loss And Body Composition Changes After Dosing With Either Placebo Or One Of Two Active Drugs
The drugs GSK189075 and GW869682 result in increased caloric losses. This study is investigating how if taken over 8 weeks that affects weight loss, food intake and the composition of the body.
- Trial name
- NCT00494767
- Testing
- GW869682, GSK189075
- Where
- United Kingdom
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Hypertension, Diabetic Nephropathy
A Study in Patients With Diabetes Mellitus Type II of the Effect on Albuminuria of 24 Week Treatment With Valsartan, Benazepril, and Valsartan+Benazepril
The purpose of this study is to evaluate the efficacy of valsartan, benazepril or the combination of both in reduction of microalbuminuria in Type 2 diabetic patients.
- Trial name
- NCT00171119
- Testing
- valsartan
- Where
- Switzerland
- Volunteers
- 81 people
- Sponsor
- Novartis Pharmaceuticals
Healthy Volunteers
A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants
The objective of this study is to assess the pharmacokinetics (PK) and absolute bioavailability of BMS-986365 and to investigate the PK, metabolite profile, routes and extent of elimination, and mass balance of BMS-986365.
- Trial name
- NCT06433505
- Testing
- BMS-986365, [14C] BMS-986365, [14C] BMS-986409 + BMS-986410
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Celgene
Healthy
A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants
The main purpose of this study is to evaluate the absorption, metabolism, and excretion (AME) profiles of pirtobrutinib (LOXO-305), to identify and characterize metabolites of pirtobrutinib (LOXO-305), and to assess the safety…
- Trial name
- NCT06180954
- Testing
- [14C]-LOXO-305, LOXO-305
- Where
- United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Neoplasms
Roniciclib Mass Balance Study
The purpose of this trial is to investigate the fate of the roniciclib (study drug) in the body in a so called mass-balance study.
- Trial name
- NCT02390154
- Testing
- roniciclib (BAY 1000394)
- Where
- Hungary
- Volunteers
- 7 people
- Sponsor
- Bayer
Advanced Solid Malignancies
Human ADME Study of [14C]-AZD1390
This is a Phase I, multicentre, single-dose, open-label study to assess the absorption, distribution, metabolism, and excretion of [14C]-AZD1390.
- Trial name
- NCT07643870
- Testing
- AZD1390
- Where
- 2 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- AstraZeneca
Healthy
Investigate Absorption, Metabolism, Excretion, and Mass Balance of Pacritinib
This study is an open-label, absorption, metabolism, excretion, and mass balance study of 400 mg [14C]pacritinib (containing 100 μCi radioactivity) administered orally as a single dose to 6 healthy male subjects following at…
- Trial name
- NCT02803762
- Testing
- Pacritinib
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- CTI BioPharma
Locally Advanced or Metastatic Solid Tumor
AZD5305 hADME in Patients With Advanced Solid Malignancies
This Phase I, open-label study aims to study to absolute bioavailability of Saruparib (AZD5305) and the absorption, distribution, metabolism and excretion (ADME) of [14C]-Saruparib in patients with advanced solid malignancies.
- Trial name
- AZD5305 (NCT06713369)
- Testing
- Saruparib (AZD5305), [14C]-AZD5305 microtracer, [14C]-AZD5305 (therapeutic dose)
- Where
- 2 sites in United Kingdom
- Volunteers
- 8 people
- Sponsor
- AstraZeneca
Healthy
Absolute Bioavailability and Metabolism Study of CORT118335 in Healthy Male Participants
This study will evaluate the absolute bioavailability of CORT118335 and determine the mass balance recovery, absorption, metabolism and elimination, and metabolite profile and identification of metabolite structures following a…
- Trial name
- NCT03878264
- Testing
- CORT118335 Oral, 14C-CORT118335 intravenous, 14C-CORT118335 oral
- Where
- United Kingdom
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Healthy
Study in Healthy Males to Assess Distribution, Metabolism, and Excretion of Radio-labelled AZD9742 Administered as a 2-hour Infusion
The purpose of this study is to assess distribution, metabolism, and excretion of radio-labelled AZD9742 administered as a 2-hour infusion to healthy male volunteers.
- Trial name
- NCT01275781
- Testing
- [14C]-AZD9742
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- AstraZeneca